Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BactiQuant AS's revenue for the
six
months ended in Jun. 2026 was €0.71 Mil.
Its revenue for the trailing twelve months (TTM) ended in Jun. 2026 was €1.28 Mil.
BactiQuant AS's Revenue per Share for the
six
months ended in Jun. 2026 was €0.02.
Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was €0.03.
Warning Sign:
BactiQuant AS revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of BactiQuant AS was -9.90% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -22.20% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -1.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 8 years, BactiQuant AS's highest 3-Year average Revenue per Share Growth Rate was 31.80% per year. The lowest was -22.20% per year. And the median was 16.50% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
BactiQuant AS Revenue Related Terms
BactiQuant AS Revenue Historical Data
* Premium members only.
The historical data trend for BactiQuant AS's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pollution & Treatment Controls subindustry, BactiQuant AS's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BactiQuant AS Revenue vs Industrial Products Industry
For the Industrial Products industry and Industrials sector, BactiQuant AS's Revenue distribution charts can be found below:
* The bar in red indicates where BactiQuant AS's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was €1.28 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BactiQuant AS (FRA:9JX) has a Revenue of €1.28 Mil as of Jun. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on BactiQuant AS and its competitors.
Is BactiQuant AS's Revenue too high?
BactiQuant AS's current Revenue is €1.28 Mil. Overall, BactiQuant AS has a GF Score™ of 52/100, reflecting its overall financial health beyond just this single metric.
How does BactiQuant AS's Revenue compare to VLTO and ZWS?
BactiQuant AS's Revenue of €1.28 Mil can be compared against companies in the Industrial Products industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for an Industrial Products company?
A good Revenue depends on the Industrial Products industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on BactiQuant AS and its competitors. BactiQuant AS's current Revenue is €1.28 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BactiQuant AS stock overvalued right now?
BactiQuant AS (FRA:9JX) has a current Revenue of €1.28 Mil. The stock's GF Value™ is €0.28, compared to a current price of €0.25 — trading 11.4% below its estimated fair value. The current Revenue is €1.28 Mil. BactiQuant AS's overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For BactiQuant AS (FRA:9JX), the current Revenue is €1.28 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BactiQuant AS (FRA:9JX) Overvalued in 2026?
Based on GuruFocus' analysis, BactiQuant AS stock appears to be undervalued.
The current stock price of €0.25 is trading 11.4% below its estimated GF Value™ of €0.28.
Key valuation signals for FRA:9JX:
Revenue: €1.28 Mil
GF Value™: €0.28 vs. price of €0.25 (11.4% below fair value)
No single metric tells the full story. See the FRA:9JX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BactiQuant AS focuses on delivering technology that ensures optimum usage and handling of water around the world. The company's activities include the development, production, sale and service of BactiQuant Online and BactiQuant Mobile Lab with associated test kits/substrate for the quantification and detection of bacteria in water. Its segments are Aquaculture, Data Centres, Oil & Gas, Water Utility, Industry, and Pharma. The group's products are BQ Online 2.0 PRO, BQ Online, BQ Mobile Lab, and Analysis Kits.
52GF Score
Get the complete analysis for FRA:9JX
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:9JX has been successfully added to your 
